Minimal clinically important differences in COPD lung function

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 2, Issue 1, 2005, Pages 111-124

  Donohue, James F ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

COPD; FEV1; Minimal difference; Spirometry

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE EXACERBATION; DISEASE SEVERITY; EQUIPMENT; FORCED EXPIRATORY VOLUME; GENERAL PRACTICE; HUMAN; LUNG FUNCTION; LUNG VOLUME; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RELAPSE; REPRODUCIBILITY; SMOKING CESSATION; SPIROMETRY; TOTAL LUNG CAPACITY;

DATA INTERPRETATION, STATISTICAL; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; SPIROMETRY;

EID: 20144382361     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1081/COPD-200053377     Document Type: Conference Paper

References (74)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946.
2. Fabbri L, Pauwels RA, Jurd S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary updated 2003. COPD 2004; 1:105-141.
3. Jaesche R, Singer J, Guyatt GH. Measurement of health status ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10:407-415.
4. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important differences (MCID): a literature review and directions for future research. Curr Opin Rheumatol 2002; 14:109-114.
5. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999; 52(9):861-873.
6. American Thoracic Society. Standardization of spirometry 1994 update. Am J Respir Crit Care Med 1995; 152:1107-1136.
7. Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the porgession of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58(11):937-941.
8. Vestbo J, TORCH Study Group. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 2004 Aug; 24(2):206-210.
9. Decramer M, Celli B, Taskin DP, Pauwels RA, Burkhart D, Cassino C, Kesten S. Clinical trial design considerations in assessing long term functional impacts of tiotropium in COPD, the uplift trial. J COPD 2004; 1(2):303-312.
10. Decramer M, Dekhuijzen PN, Troosters T, van Herwaarden C, et al. The bronchitis randomized on NAC Cost-utility study (BRONCUS): hypothesis and design. BRONCUS-trial committee. Lancet 2005, In press.
11. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha 1-antitrypsin. Am J Respir Crit Care Med 1998; 158:49-59.
12. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey W, Buist SS, Tashkin DP, Lung Health Study Research Group. Smoking Cessation and lung Function in Mild-to-Moderate Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2000; 162:381-390.
13. Celli RB, Cote CG, Martin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Eng J Med 2004; 350:1005-1012.
14. Nishamura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121:1434-1440.
15. Hansen EF, Phanareth K, Laursen LS, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159:1267-1271.
16. Casabari R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr, US Tiotropium Study Group. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 2000; 118:1294-1302.
17. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ Jr, Kesten S, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47-55.
18. Donohue JF, Kalberg C, Emmett A, Merchant K, Knobil K. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med 2004; 3(3):173-181.
19. Hanania NA, Darken P, Horstam D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 μg/ salmeterol [50 μg]) combined in the diskus inhaler for the treatment of COPD. Chest 2003; 124(3):834-843.
20. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1084-1091.
21. Vincken W, van Noord JA, Greefhort APM, Bantje TA, Kesten S, Korducki L, Cornelissen PJG, Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19(2):209-216.
22. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58:399-404.
23. Gross NJ, Petty TL, Friedman M, Skordin MS, Silvers GW, Donohue JF. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis May 1989; 139(5):1188-1191.
24. Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Cioppa GD, Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121:1058-1069.
25. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows, report working party standardization of lung function tests. Official statement of the European respiratory society. Eur Respir J 1993; 16(suppl):5-40.
26. American Thoracic Society. Standardization of spirometry; 1987 update. Am Rev Respir Dis 1987; 136:1286-1296.
27. Hankinson JL, Bang KM. Acceptability and reproducibility criteria of the American thoracic society as observed in a sample of the general population. Am Rev Repsir Dis 1991; 143:516-521.
28. Schermer TR, Jacobs JE, Chavannes NH, Hartman J, Folgering HT, Bottema BJ, van Weel C. Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD). Thorax 2003 Oct; 58(10):861-866.
29. Townsend MC, Hankinson JL, Lindesmith LA, Slivka WA, Stiver G, Ayres GT. Is my lung function really that good? Flow-type spirometer problems that elevate test results. Chest 2004; 125(5): 1902-1909.
30. Santus P, Pecchiari M, Carlucci P, Boveri B, Di Marco F, Castagna F, Centanni S. Bronchodilation test in COPD: effect of inspiratory manoeuvre preceding forced expiration. Eur Respir J 2003;21(1):82-85.
31. Sharafkhanek A, Officer TM, Goodnight-White S, Rodart JR, Borek AM. Novel method for measuring effects of gas compression on expiratory flow. Am J Physiol Regal Integr Comp Physiol 2004; 287:R479-R484.
32. Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1965; 1:775-779.
33. 1? Lancet 1996; 2:618-619.
34. Joyce DP, Jackevicius C, Chapman KR, McIvor RA, Kesten S. The placebo effect in asthma drug therapy trials: a meta-analysis. J Asthma 2000 Jun; 37(4):3003-3018.
35. Enright PL, Beck KC. Sherrill, repeatability of spirometry in 1,800 adult patients. Am J Respir and Crit Care Med 2004; 169:235-238.
36. 1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987; 42:487-490.
37. Wise RA, Connett J, Kurnow K, Grill J, Johnson L, Kanner R, Enright P, Lung Center Study Group. Selection of spirometric measurements in a clinical trial, the lung health study. Am J Respir Crit Care Med 1995; 151:1675-1681.
38. Brand PL, Quanjer PH, Postma DS, Kerstjens HA, Koeter GH, Dekhuijzen PN, Sluiter HJ. Interpretation of bronchodilator response in patients with airways disease. The Dutch chronic non-specific lung disease (CNSLD) study group. Thorax 1992; 47(6):429-436.
39. Hankinson JL, Crapo RO, Jensen RL. Spirometric reference values for the 6-s FVC maneuver. Chest 2003 Nov; 124(5):1805-1811.
40. 6 is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. Am J Respir Crit Care Med 2000; 162(3):917-919.
41. 6 predicts lung function decline in adult smokers. Respir Med 2002; 96:444-449.
42. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:1557-1565.
43. Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, Cazzola M, Centanni S. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003; 21:86-94.
44. Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121:1042-1050.
45. Redelmeier DA, Goldstein RS, Min ST, Hyland RH. Spirometry and dyspnea in patients with COPD: when small differenced mean little. Chest 1996; 109:1163-1168.
46. Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J 1999; 14(1):23-27.
47. 1 to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:991201-991205.
48. Singh JM, Palda VA, Stanbrook MB, Chapman KR. Corticosteroids therapy for patients with acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2002; 162:2527-2536.
49. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999; 354:456-460.
50. Aaron SD, Vandemheen KL, Herbert P, Dale R, Stiell KT, Ahuja J, Dickinson G, Brison R, Rowe BH, Dreyer J, Yetisir E, Cass D, Well G. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J 2003; 26:2618-2625.
51. Fletcher C, Peto R, Tinker C. The Natural History of Chronic Bronchitis and Emphysema. New York: Oxford University Press, 1976:1-272.
52. 1, the lung health study. JAMA 1994; 272(19): 1497-1505.
53. 1 in patients with chronic obstructive pulmonary disease. Ann Intern Med 2003; 138:969-973.
54. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328:1519.
55. 2-agonists for stable chronic obstructive pulmonary disease (Cochran review). Cochrane Database Syst Rev (database online) 2003; (2), Accessed July 10, 2003.
56. Calvery P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsrik A. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356):449-456.
57. Sin DD, McAlister FA, Man SFP, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease. JAMA 2003; 290(17):2301-2316.
58. 2-anonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation (Cochrane review). Cochrane Database 2003; (2), Accessed July 10, 2003.
59. van Noord JA, Smeets JJ, Custers FLJ, Korducki L, Cornelissen PJ. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19:639-644.
60. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilanice B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolernace in COPD. Eur Respir J 2004; 23:832-840.
61. Burge PS, Calvery PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. On behalf of the ISOLDE study investigators. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1305.
62. Hanania NA, Darken P, Horstam D, Reisner C, Lee B, Davis S, Shan T. The efficacy and safety of fluticasone propionate (250 μg/ salmeterol [50μg]) combined in the diskus inhaler for the treatment of COPD. Chest 2003; 124(3):834-843.
63. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994 May; 105(5):1411-1419.
64. COMBIVENT Inhalation Aerosol Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997 Dec; 112(6):1514-1521.
65. Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ Jr. Pharmacoeconomics evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115:635-641.
66. Lanes SF, Garrett JE, Wentworth CE, Fitzgerald JM, Karpel JP. The effect of adding ipratropium bromide to salmeterol in the treatment of acute asthma: a pooled analysis of three trials. Chest 1998 Aug; 114(2):365-372.
67. Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W. A comparison of inhaled ipratropium, oral theophylline plus inhaled beta-agonist, and the combination of all three in patients with COPD. Chest 1994 Apr; 105(4):1089-1094.
68. Zuwallach RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, Knobil K. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119:1661-1670.
69. van Noord JA, de Munck AJ, Bantje TA, Hop WCJ, Akveld MLM, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15:878-885.
70. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003; 97:1014-1020.
71. Chabra SK, Bhatnagar S. Comparison of bronchodilator responsiveness in asthma and chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 2002; 44:91-97.
72. Kesten S, Rebuck AS. Is the short-term response to inhaled β-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest 1994; 105:1042-1045.
73. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283-1289.
74. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayers JG, Creemers JP, Schultze-Werninghaus G, Brambilla C, Barnes NC. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001; 358:265-270.